TB

Tippingpoint Bio

Pioneering new therapies for diseases of chromatin dysfunction

San Francisco, United States · Founded 2023 · $4.5M raised

Employees
1–10
Founded
2023
Business Model
B2B
Total Funding
$4.5M
Last Round
$4.5M SeedApr 2026
Rounds
1

About

TippingPoint Biosciences is an early-stage therapeutic company spun out of Dr. Geeta Narlikar's lab at UCSF, built around a novel drug discovery platform designed to identify first-in-class drugs targeting diseases related to dysfunctional DNA packaging (chromatin). It is the first company to develop a screening platform enabling direct targeting of defective chromatin in disease cells without affecting healthy cells, with applications spanning cancer, neurodegenerative disease, and developmental disorders. Its lead program targets Diffuse Intrinsic Pontine Glioma, a deadly pediatric brain cancer.

Summary

Tippingpoint Bio is a Biotech company based in San Francisco, United States, founded in 2023. It has raised $4.5M in total across 1 round, most recently a $4.5M Seed round in Apr 2026. Investors include SOSV and LKS Fund.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SeedSeed RoundApr 2026
$4.5M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Tippingpoint Bio on Indexed.vc
<a href="https://indexed.vc/companies/tippingpoint-bio"><img src="https://indexed.vc/api/badge/company/tippingpoint-bio" alt="Tippingpoint Bio on Indexed.vc" width="260" height="76" /></a>